维格列汀与二甲双胍对初诊2型糖尿病的疗效  

Effects of vildagliptin and metformin on newly diagnosed type 2 diabetes mellitus patients

作　　者：史治宙[1] 廖庆辉[1] 郭中秋[1] 谭娅琴[1] 赖康宝 陈玉华[1] 

机构地区：[1]深圳市龙岗区人民医院内分泌科,广东深圳518072

出　　处：《热带医学杂志》2016年第9期1159-1162,共4页Journal of Tropical Medicine

摘　　要：目的观察维格列汀联合二甲双胍对新诊断2型糖尿病患者的疗效。方法 59例新诊断2型糖尿病患者依据随机数字表随机分为维格列汀组(n=20)、二甲双胍组(n=20)、维格列汀和二甲双胍联合治疗组(n=19),比较治疗前后三组患者空腹及餐后2 h血糖、胰岛素(FPG、2h PG、Fins、2h Ins)水平,糖化血红蛋白(Hb Alc)水平,计算胰岛β细胞功能指数(HOMA-β)及胰岛素抵抗指数(HOMA-IR)。结果三组患者血糖水平及Hb Alc较治疗前均降低(P<0.05);HOMA-β较治疗前升高(P<0.05);HOMA-IR较治疗前有降低,仅二甲双胍组及联合治疗组差异有统计学意义(P<0.05)。组间比较联合治疗组各监测指标改善最明显(P<0.05)。三组均未出现肝肾功能异常亦无低血糖事件报告。结论维格列汀联用二甲双胍可以良好控制新诊断2型糖尿病患者血糖,改善胰岛β细胞功能。Objective To evaluate the clinical effect of vildagliptin combined with metromain on the treatment of newly diagnosed type 2 diabetes mellitus（T2DM）. Methods 59 patients with T2 DM were randomly divided into vildagliptin group（group W,20 patients）, mefformin group（group M, 20 patients） and vildagliptin combined with metformin group（group U, 19 patients）. Before and after therapy, fasting and 2 hour postrandial blood glucoseand insulin were determined（FPG,2h PG,Fins,2hins）, and glycosylation hemodobin（HbAlc） was also determined, while homeostasis model assessment was applied to estimate the function index of islet B cell（HOMA-β） and HOMA-IR. Results Compared with before treatment, the levels of blood glucose and HbAlC were decreased significantly in all groups（P〈0.05）. HOMA-βwas significantly higher（P〈0.05） and HOMA-IR was lower after treatment, and the changes between group M and U were significantly different（P〈0.05）. All the indexes of group U were the significantly better than those of the other groups（P〈0.05）. Conclusion Vildagliptin combined with metformin could significantly improve the glycaemic control and the function of islet β cell.

关 键 词：维格列汀 二甲双胍 2型糖尿病 

分 类 号：R587.1[医药卫生—内分泌]